Home

Celerion Recognized as a Leading Contract Research Organization for the 4th Consecutive Year

content — Wed, 27 Mar 2019 23:28:01 +0000

For the fourth consecutive year, biopharmaceutical industry executives have selected Celerion as an industry leader in multiple categories of Life Science Leader’s annual CRO Leadership Awards. Celerion was recognized as a leader within the Small Pharmaceutical company group as well as a leader in the Overall group (Combined Big and Small Pharma). Celerion has won […]

The post Celerion Recognized as a Leading Contract Research Organization for the 4th Consecutive Year first appeared on World Pharma Today.

Sygnature Discovery Continues Strong Growth Trajectory with Two Senior Appointments

content — Sat, 16 Feb 2019 00:32:26 +0000

Sygnature Discovery, the leading independent integrated drug discovery and pre-clinical services provider, have made two key appointments. Dr. Allan Jordan and Ms. Louisa Jordison have joined the organisation as they continue their strong growth trajectory in the drug research market. Allan comes on-board as Director of Oncology Drug Discovery and in this new role his […]

The post Sygnature Discovery Continues Strong Growth Trajectory with Two Senior Appointments first appeared on World Pharma Today.

CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery

content — Wed, 09 Jan 2019 02:00:53 +0000

CytoReason, a leader in machine learning for drug discovery and development, announced that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support […]

The post CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery first appeared on World Pharma Today.

GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus

Yuvraj — Fri, 23 Mar 2018 05:07:08 +0000

GSK today announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE). Belimumab and rituximab have different but potentially complementary mechanisms of action. This study will assess whether co-administration enhances the treatment effect of belimumab and provides sustained disease control, which could […]

The post GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus first appeared on World Pharma Today.